Related Experiment Video
Updated: Jul 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
[Update of combined therapies with docetaxel for hormone-independent prostate cancer]
1Department of Urology, Yunnan Urology Research Laboratory, the Second Hospital Affiliated to Kunming Medical College, Kunming, Yunnan 650101, China. libing7929@sina.com
Abstract:
Hormone-independent prostate cancer (HIPC) is the end stage of prostate cancer, with a short median survival of 9-18 months for the patients. Two large phase III studies have demonstrated a survival advantage of docetaxel chemotherapy in HIPC patients. New combined protocols have been developed with promising results. These protocols propose a combination with docetaxel, chemotherapy, antiangiogenic agents, vaccine and biological drugs. This review focuses the progress achieved the combined therapies for HIPC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
